Alembic Pharmaceuticals Limited has informed the Exchange about press release dated 27-Oct-2022 titled Alembic Pharmaceuticals receives USFDA Final Approval for Paclitaxel Injection USP, 30 mg/5 mL (6 mg/mL), 100 mg/16.7 mL (6 mg/mL), and 300 mg/50 mL (6 mg/mL) Multiple-Dose Vials.